Humana (NYSE:HUM) Releases FY24 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $16.00 for the period, compared to the consensus estimate of $16.34.

Humana Stock Up 1.3 %

Shares of Humana stock traded up $4.64 during trading hours on Friday, hitting $363.62. 1,076,306 shares of the company’s stock traded hands, compared to its average volume of 1,396,067. The stock has a 50 day simple moving average of $367.90 and a 200-day simple moving average of $347.35. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The company has a market cap of $43.78 billion, a PE ratio of 22.64, a PEG ratio of 2.09 and a beta of 0.51. Humana has a twelve month low of $298.61 and a twelve month high of $530.54.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm earned $8.94 earnings per share. Equities research analysts anticipate that Humana will post 16.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HUM has been the subject of several recent analyst reports. Bank of America raised their target price on Humana from $342.00 to $376.00 and gave the company a neutral rating in a research note on Monday, May 20th. Wells Fargo & Company decreased their price target on Humana from $413.00 to $350.00 and set an overweight rating for the company in a research note on Monday, April 8th. Robert W. Baird started coverage on Humana in a research note on Thursday, May 30th. They issued a neutral rating and a $374.00 price target for the company. Truist Financial lifted their price target on Humana from $355.00 to $400.00 and gave the stock a hold rating in a research note on Monday, July 15th. Finally, UBS Group decreased their price target on Humana from $334.00 to $326.00 and set a neutral rating for the company in a research note on Thursday, April 25th. Fourteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Humana presently has a consensus rating of Hold and a consensus target price of $403.55.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.